As most mouse models of atherosclerosis are nonresponsive to statins and PCSK9 inhibitors due to the critical role of the LDLR in their therapeutic mechanisms23–25, we performed lesion regression studies in LDLR KO mice. This evidence concerns the gene PCSK9 and atherosclerosis.